These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33685799)

  • 1. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
    Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
    Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
    Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
    Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent PD-L1 expression in testicular germ cell tumors.
    Fankhauser CD; Curioni-Fontecedro A; Allmann V; Beyer J; Tischler V; Sulser T; Moch H; Bode PK
    Br J Cancer; 2015 Jul; 113(3):411-3. PubMed ID: 26171934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in testicular germ cell tumors undergoing spontaneous regression.
    Novak I; Tomić M; Mulabdić D; Pezelj I; Čiček S; Tomašković I; Sinčić N; Krušlin B; Ulamec M
    Biomol Biomed; 2024 Oct; 24(6):1751-1760. PubMed ID: 38943678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases.
    Tarrant WP; Czerniak BA; Guo CC
    Hum Pathol; 2013 Oct; 44(10):2220-6. PubMed ID: 23856516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase II alpha expression in testicular germ cell tumors.
    Dimov ND; Zynger DL; Luan C; Kozlowski JM; Yang XJ
    Urology; 2007 May; 69(5):955-61. PubMed ID: 17482942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
    Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
    Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic findings and clinical outcomes in patients who required neoadjuvant chemotherapy before orchiectomy for testicular germ cell tumors.
    Stump JA; Acosta AM; Whaley RD; Cheng L; Fang AM; Rais-Bahrami S; Gordetsky JB
    Hum Pathol; 2022 Oct; 128():48-55. PubMed ID: 35817140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of MDR1-expression in testicular germ cell cancer.
    Schrader AJ; Seger M; Konrad L; Olbert P; Hegele A; Hofmann R; Heidenreich A
    Exp Oncol; 2007 Sep; 29(3):212-6. PubMed ID: 18004247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
    Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
    Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.
    Balzer BL; Ulbright TM
    Am J Surg Pathol; 2006 Jul; 30(7):858-65. PubMed ID: 16819328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SALL4 is a novel diagnostic marker for testicular germ cell tumors.
    Cao D; Li J; Guo CC; Allan RW; Humphrey PA
    Am J Surg Pathol; 2009 Jul; 33(7):1065-77. PubMed ID: 19390421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis.
    Li P; Zhong Y; Zhang M; Zheng Y; Peng W
    Transl Cancer Res; 2024 Aug; 13(8):3944-3959. PubMed ID: 39262473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
    Liu X; Choi MG; Kim K; Kim KM; Kim ST; Park SH; Cristescu R; Peter S; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152881. PubMed ID: 32089413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; Mego M; Mardiak J
    BMC Cancer; 2018 Nov; 18(1):1062. PubMed ID: 30390643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.